MYELOFIBROSIS (MF)
Clinical trials for MYELOFIBROSIS (MF) explained in plain language.
Never miss a new study
Get alerted when new MYELOFIBROSIS (MF) trials appear
Sign up with your email to follow new studies for MYELOFIBROSIS (MF), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo may boost stem cell success in rare bone marrow cancer
Disease control Not yet recruitingThis study tests whether the drug gecacitinib can help people with myelofibrosis (a serious bone marrow disorder) who are getting a stem cell transplant. About 39 adults will receive the drug before, during, and after their transplant. The goal is to see if it reduces serious com…
Matched conditions: MYELOFIBROSIS (MF)
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 17, 2026 05:47 UTC
-
Which drug wins for myelofibrosis? new trial pits momelotinib against ruxolitinib
Disease control Not yet recruitingThis study tests two FDA-approved drugs, momelotinib and ruxolitinib, in people with myelofibrosis who also have low blood cell counts. The main goal is to see which drug is better at shrinking the spleen and reducing the need for blood transfusions. About 268 participants will b…
Matched conditions: MYELOFIBROSIS (MF)
Phase: PHASE4 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New study tracks Real-World impact of momelotinib on enlarged spleens in myelofibrosis
Disease control Not yet recruitingThis study will observe 93 adults with myelofibrosis who are starting momelotinib as part of their normal care. Researchers want to see how well the drug reduces an enlarged spleen after 6 months. The goal is to understand the drug's real-world effectiveness beyond clinical trial…
Matched conditions: MYELOFIBROSIS (MF)
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New hope for blood cancer patients: drug may prevent post-transplant anemia
Disease control Not yet recruitingThis study tests whether the drug luspatercept can prevent severe anemia (low red blood cells) after a stem cell transplant in people with blood cancers who also have moderate to severe bone marrow scarring (myelofibrosis). About 196 adults aged 18-65 will be randomly assigned to…
Matched conditions: MYELOFIBROSIS (MF)
Phase: PHASE2, PHASE3 • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated May 12, 2026 13:43 UTC
-
Can patients safely stop Anti-Rejection drugs sooner after transplant?
Disease control Not yet recruitingThis study tests whether patients who receive a stem cell transplant for blood cancers can safely stop taking the immune-suppressing drug tacrolimus earlier than usual. The goal is to reduce side effects while still preventing graft-versus-host disease (GVHD), a common complicati…
Matched conditions: MYELOFIBROSIS (MF)
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated May 05, 2026 11:56 UTC
-
New drug ZE74-0282 targets rare blood cancers in early trial
Disease control Not yet recruitingThis early-stage trial tests an experimental drug, ZE74-0282, in about 60 adults with blood cancers like polycythemia vera or myelofibrosis caused by a JAK2 mutation. The main goals are to find the safest dose and check for side effects, while also seeing if the drug shows any si…
Matched conditions: MYELOFIBROSIS (MF)
Phase: PHASE1 • Sponsor: Eilean Therapeutics • Aim: Disease control
Last updated May 04, 2026 16:31 UTC